BG Medicine, Inc.
BGMD · OTC
12/31/2015 | 9/30/2015 | 6/30/2015 | 3/31/2015 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.02 | -0.05 | -0.78 |
| FCF Yield | -27.17% | -8.31% | -4.34% | -4.97% |
| EV / EBITDA | -2.93 | -1.35 | -10.57 | -23.01 |
| Quality | ||||
| ROIC | -94.65% | -72.84% | 242.04% | -91.28% |
| Gross Margin | 71.72% | 69.16% | 65.94% | 65.90% |
| Cash Conversion Ratio | 1.24 | 0.32 | 0.41 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.28% | -22.92% | -15.31% | -8.30% |
| Free Cash Flow Growth | -236.45% | 59.85% | 40.55% | -30.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.73 | 2.64 | -0.77 | -0.20 |
| Interest Coverage | 0.00 | -256.50 | -22.94 | -13.65 |
| Efficiency | ||||
| Inventory Turnover | 0.57 | 0.46 | 0.57 | 0.53 |
| Cash Conversion Cycle | -397.12 | -928.07 | -116.76 | -153.42 |